Published in final edited form as:

Drug Alcohol Depend. 2019 January 01; 194: 40–44. doi:10.1016/j.drugalcdep.2018.10.005.

Young adult dual combusted cigarette and e-cigarette users' anticipated responses to a nicotine reduction policy and menthol ban in combusted cigarettes*

Lauren R. Pacek^a, Jason A. Oliver^a, Maggie M. Sweitzer^a, and F. Joseph McClernon^a

^aDepartment of Psychiatry and Behavioral Sciences, Duke University School of Medicine, 2608 Erwin Road, Suite 300, Durham, NC 27705

Abstract

Background: The aim of the study was to assess young adult dual e-cigarette (EC) and combusted cigarette (CC) users' anticipated responses to a hypothetical very low nicotine content product standard and menthol ban in CC.

Methods: Data came from 240 young adult (18–29 years) dual CC and EC users recruited via Amazon Mechanical Turk between June 20–22, 2017. Descriptive statistics were used to report sample characteristics. McNemar's tests were used to assess differences between product categories in terms of anticipated responses to hypothetical regulations.

Results: A hypothetical very low nicotine content product standard in CC resulted in reported intentions to quit or reduce CC use and increase use of EC (p 's < 0.001). Hypothetical restrictions regarding the availability of menthol CC resulted in marginally significant reported intentions to increase EC use ($p = 0.080$). Anticipated responses to regulation were associated with baseline EC and CC use characteristics.

Conclusions: This work provides preliminary evidence of the impact that regulations regarding nicotine content and menthol in CC may have on the use of EC among young adult dual users.

Keywords

nicotine reduction; menthol; e-cigarettes; cigarettes; dual use; tobacco regulatory science

Correspondence Lauren Pacek, Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, 2608 Erwin Road, Suite 300, Durham, NC 27705, lauren.pacek@duke.edu, Phone – 919-684-5437.

Contributors

Authors Pacek and McClernon conceptualized the research question, author Pacek conducted the statistical analyses, and wrote the first draft of the manuscript. Authors Oliver, Sweitzer, and McClernon contributed to, have critically reviewed and revised, and have approved of the final manuscript.

Conflict of Interests

The authors have no conflicts of interest to declare.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1. Introduction

The Family Smoking Prevention Tobacco Control Act (FSPTCA) provided the United States (U.S.) Food and Drug Administration (FDA) with regulatory authority over the manufacture, marketing, and distribution of combusted cigarettes (CC) (U.S. Congress, 2009). The FDA is authorized to reduce the maximum allowable nicotine content in CC. Reducing nicotine in CC to a level below that which sustains dependence could help smokers to reduce smoking or quit, and decrease the likelihood of dependence in smokers (Benowitz and Henningfield, 1994; Donny et al., 2017). A nicotine reduction policy could have beneficial effects by reducing the number of CC smoked per day, nicotine dependence, and toxicant exposure (Benowitz et al., 2007; Denlinger et al., 2016; Donny et al., 2015; Hatsukami et al., 2010; Mercincavage et al., 2016), while resulting in minimal unintended consequences (e.g., alcohol and cannabis use, depression) (Dermody et al., 2016; Pacek et al., 2016; Tidey et al., 2017).

Additionally, the FSPTCA established a tobacco standard special rule that banned the use of characterizing flavors in CC (U.S. Congress, 2009). Though menthol was specifically exempted from prohibition under the FSPTCA, the law also included a provision authorizing the FDA to issue additional product standards related to addressing flavors in tobacco products. There has been renewed interest in banning menthol as a characterizing flavor in CC (FDA, 2018). This is significant given the conclusions drawn from a 2013 review of the scientific literature by the FDA, in which it was determined that it is “likely that menthol cigarettes pose a public health risk above that seen with non-menthol cigarettes” (FDA, 2013). A systematic review also concluded that the strength and consistency of the associations in reviewed studies supports the hypothesis that removing menthol as a characterizing flavor from CC is likely to reduce youth initiation, improve smoking cessation outcomes in adult smokers, and subsequently benefit the public health (Villanti et al., 2017).

However, it remains unknown how such policies might impact the use of other tobacco products. It is critical to anticipate how potential restrictions on the CC market may impact CC and other tobacco product—such as EC—use (Pacek et al., 2018). Regulations applicable to a single tobacco product also impact the use of other tobacco products. While increases in taxation on CC result in decreases in the prevalence of CC use, they have also resulted in increased use of other tobacco products like cigars and smokeless tobacco (Delnevo et al., 2004; Hawkins et al., 2018). According to data from the National Youth Tobacco Survey, the FSPTCA ban on flavored cigarettes led to decreased CC smoking, but an increase in the use of cigars and pipes among current adolescent smokers (Courtemanche et al., 2017). Some research also indicates that a very low nicotine content (VLNC) standard in CC may increase the use of non-CC tobacco products (Hatsukami et al., 2017).

Anticipating whether regulations regarding VLNC and a ban on menthol in CC will impact the use of other tobacco products is of particular importance among young adults (i.e., age 18–29). Dual and multiple tobacco product use is common (46%) in this age group (Soneji et al., 2016) and young adulthood represents a pivotal developmental period for the acquisition and escalation of tobacco product use and dependence (USDHHS, 2014). We

aimed to assess young adult dual CC and e-cigarette (EC) users' anticipated responses to hypothetical market restrictions regarding nicotine content and menthol CC availability.

2. Methods

2.1 Data source

Data were collected on Amazon Mechanical Turk (MTurk). Inclusion criteria were: U.S. residents; age 18–29; smoking CC for ≥ 3 months AND ≥ 1 day in the past week; and using EC for ≥ 3 months AND ≥ 1 day in the past week; a ≥ 95% approval rating from previous MTurk tasks. Eligible participants were given a code to access the survey, hosted by Qualtrics (Provo, UT). The survey was active from June 20–22, 2017. Participation was voluntary and anonymous (i.e., no IP addresses were recorded) and participants were compensated \$2 for participation. Even though IP addresses were not recorded, selecting the “Prevent Ballot Box Stuffing” option in Qualtrics—located under Survey Options—prevents respondents from taking a survey multiple times by placing a cookie on their browser when they submit a response. The next time the respondent clicks on the survey link, Qualtrics will see this cookie and not permit them to take the survey (Qualtrics Support, 2018). As in our prior research (Johnson et al., 2017; Pacek et al., 2017; Rass et al., 2015), participants were asked “Do you feel that you took your time with this survey and that we should use your responses? You will be paid for this HIT regardless of your response to this question.” Individuals who responded “No, I was rushed or distracted, so you would be better off not including my data” were not included in the present analyses. The Institutional Review Board at Duke University approved this study.

2.2 Measures

2.2.1 Sociodemographic, CC and EC history characteristics.—Participants reported sociodemographic information and detailed CC/EC use history. The Perceived Health Risks (PHR) scale (Hatsukami et al., 2016) asked participants to indicate what they believed their risks (scale from 1–10) of developing various conditions to be based on their current CC and EC use (assessed separately). As in prior research (Pacek et al., 2018a; 2018b), we used an average measure of all of the assessed conditions. The Fagerström Test for Nicotine Dependence (Heatherton et al., 1991) (FTND) assessed CC dependence and a modified version (i.e., eFTND) assessed EC dependence (Rass et al., 2015).

2.2.2 Hypothetical CC market restrictions.—Participants were presented with two potential regulations regarding CC, separately, and reported their anticipated responses. The first hypothetical scenario was: “Imagine that EC available in the United States are like they are today BUT all regular cigarettes have a very low nicotine content. Second, participants were asked to “Imagine that EC available in the United States are like they are today BUT only non-menthol regular cigarettes are available (i.e., menthol cigarettes are no longer available).” Under each scenario, participants indicated—separately for CC and EC—whether they would stop using CC/EC completely, use CC/EC a lot less often, use CC/EC a little less often, use CC/EC the same amount, use CC/EC a little more often, or use CC/EC a lot more often. The question about a menthol ban was only asked of menthol CC smokers.

2.3 Statistical analysis

Descriptive statistics depicted the sociodemographic and CC/EC use characteristics of the sample. McNemar's tests—a statistical test used on paired nominal data to determine whether the row and column marginal frequencies are equal—were used to assess differences between product use categories in terms of anticipated responses to hypothetical CC market restrictions. Multinomial logistic regression assessed correlates of anticipated CC and EC use following hypothetical nicotine content and menthol restrictions in CC. Variables in adjusted models were selected based on *a priori* theory as well as $p < 0.10$ in bivariate models. Multicollinearity among variables in adjusted models was not an issue (i.e., all VIF values < 1.5). Analyses were performed using STATA SE version 15 (StataCorp, 2017).

3. Results

3.1 Sample characteristics

In total, 252 individuals completed the survey. Twelve participants were excluded for: not meeting EC use inclusion criteria ($n=3$); indicating that their data should not be used ($n=8$); and unreliable data (e.g., inconsistent responding; $n=4$). Numbers do not sum to 12 because of overlap between some of the categories. Analyses are based on a final sample size of $n=240$. Sociodemographic characteristics are presented in Table 1 and CC and EC use characteristics are presented in Table 2.

3.2 Responses to hypothetical CC regulations

Participants were more likely to report intentions to quit ($\chi^2(1, N=240)=14.5, p<0.001$) or reduce ($\chi^2(1, N=240)=14.4, p<0.001$) CC versus EC use and more likely to report intentions to increase EC versus CC use ($\chi^2(1, N=240)=26.7, p<0.001$) in response to a hypothetical VLNC standard in CC (Figure 1a). In response to hypothetical restrictions regarding menthol CC, a trend for significance was observed whereby participants reported intentions to increase EC versus CC use ($\chi^2(1, N=126)=3.06, p=0.080$) (Figure 1b).

3.3 Correlates of anticipated responses to a VLNC product standard

3.3.1 EC use.—Using EC on a greater number of days during the past week was associated with a decreased likelihood of anticipating reduced versus maintained EC use (aRRR=0.75, 95% CI=0.63–0.90) (Supplementary Table 1a¹). Greater FTND scores were associated with a greater likelihood of anticipating reduced versus maintained EC use (aRRR=1.36, 95% CI=1.12–1.64).

3.3.2 CC use.—Greater risk perceptions of CC were associated with an increased likelihood of anticipating reduced versus maintained CC use (aRRR=1.22, 95% CI=1.02–1.46) (Supplementary Table 1b¹). Intentions to quit CC use were associated with greater likelihood of anticipating quitting versus maintaining CC use (aRRR=4.90, 95% CI=1.74–

¹Supplementary material can be found by accessing the online version of this paper at <http://dx.doi.org> and by entering doi:..

13.85). Greater health risk perceptions of EC were associated with a decreased likelihood of anticipated increased versus maintained CC use (aRRR=0.81, 95% CI=0.66–0.99).

3.4 Correlates of anticipated responses to a menthol ban

3.4.1 EC use.—Using EC on a greater number of days during the past week was associated with a decreased likelihood of anticipated reduced versus maintained EC use following a menthol ban in CC (aRRR=0.72, 95% CI=0.54–0.95) and using a greater number of cigarettes per day (CPD) was associated with a greater likelihood of anticipated reduced versus maintained EC use (aRRR=1.17, 1.02–1.35) (Supplementary Table 2a²). Greater health risk perceptions of EC were associated with a decreased likelihood of anticipated increased versus maintained EC use (aRRR=0.78, 95% CI=0.63–0.97).

3.4.2 CC use.—Using EC on a greater number of days during the past week (aRRR=1.51, 95% CI=1.11–2.07), intentions to quit EC use (aRRR=6.08, 95% CI=1.51–24.46), and greater FTND scores (aRRR=1.42, 95% CI=1.03–1.97) were associated with increased likelihoods of quitting versus maintaining CC use (Supplementary Table 2b²). Conversely, using CC on a greater number of days during the past week was associated with a decreased likelihood of quitting versus maintaining CC use (aRRR=0.58, 95% CI=0.41–0.83). Smoking more CPD was associated with an increased likelihood of increased versus maintained CC use (aRRR=1.22, 95% CI=1.01–1.46).

4. Discussion

This work provides preliminary evidence that implementing a VLNC product standard for CC may lead to dual CC/EC users intending to reduce or quit use of CC, while intending to simultaneously increase EC use. This is consistent with prior research: In a sample of daily CC smokers randomized to smoke cigarettes with varying nicotine content for six weeks, significantly more participants randomized to the VLNC groups compared to the control group reported that, in a year, they would stop smoking if the study cigarette was the only CC available for purchase (Smith et al., 2017). Additionally, in a study in which participants were randomized to smoke normal or VLNC cigarettes and given access to non-cigarette combusted (e.g., cigarillos) and non-combusted tobacco products (e.g., EC, and medicinal nicotine), there were higher rates of non-combusted tobacco product use—EC in particular—among persons randomized to smoke VLNC cigarettes (Hatsukami et al., 2017). When viewed from a harm reduction perspective, decreases in CC use combined with simultaneous increases in non-combusted tobacco product use in response to a VLNC product standard can arguably be viewed as a favorable outcome. However, the potential for regulations on CC to influence use of other tobacco products must be weighed carefully throughout this process.

There was a trend for significance regarding intentions to increase EC use in response to a menthol ban in CC. Given that this question was only asked of participants who reported smoking menthol cigarettes (n=126), it is possible these analyses were underpowered.

²Supplementary material can be found by accessing the online version of this paper at <http://dx.doi.org> and by entering doi:...

Regardless, this is consistent with prior work indicating that, among dual CC and EC users, elimination of flavored e-liquids resulted in intentions to maintain or increase CC use (Pacek et al., 2018). Additionally, various EC and CC use characteristics were associated with anticipated responses to hypothetical tobacco product regulations (e.g., greater health risk perceptions of CC are associated with anticipated reductions in CC use following a VLNC product standard), suggesting that responses to regulations on tobacco products may be dictated by factors beyond simply the regulations themselves. Moreover, given that some findings were potentially unexpected (e.g., greater FTND scores associated with greater likelihood of anticipating reduced use), future work is needed to further explore factors that are associated with responses—anticipated and actual—to potential regulations.

This work should be considered in light of several limitations. Although recent work indicates that data from substance-using samples gathered via MTurk are valid (Mortensen and Hughes, 2018), individuals in the present sample may differ from young adult dual users in the U.S. general population (Richardson et al., 2014; Soneji et al., 2016). Because data were collected via self-report, we do not have biochemical verification of CC and EC use. Participants' responses regarding anticipated CC and EC use were based on hypothetical scenarios; Future work should evaluate dual users' behavioral responses to market regulations in the context of laboratory and/or clinical trials research. Additionally, anticipated tobacco product use in response to hypothetical regulations was only assessed for CC and EC. Future work should evaluate anticipated use of additional tobacco products.

Dual and multiple tobacco product use is common among young adults, and young adulthood represents a critical period in terms of the uptake and escalation of tobacco product use. Thus, it is important to anticipate how regulatory efforts targeted at one product may impact the use of not only the targeted product, but also whether and how they impact the use of other tobacco products (e.g., EC) (Pacek et al., 2018). Our findings indicate that a VLNC product standard in CC result in decreases in use of CC and increases in the use of EC among young adult dual CC/EC users.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Role of the Funding Sources

This work was supported by the National Institutes of Health (K01DA043413, K23DA039294, and K23DA042898).

References

- Benowitz NL, Hall SM, Stewart S, Wilson M, Dempsey D, Jacob P, 2007 Nicotine and carcinogen exposure with smoking of progressively reduced nicotine content cigarette. *Cancer Epidemiol. Biomarkers Prev* 16, 2479–2485. 10.1158/1055-9965.EPI-07-0393. [PubMed: 18006940]
- Benowitz NL, Henningfield JE, 1994 Establishing a nicotine threshold for addiction. The implications for tobacco regulation. *N. Engl. J. Med* 331, 123–125. 10.1056/NEJM199407143310212. [PubMed: 7818638]

- Carter RR, DiFeo A, Bogie K, Zhang G-Q, Sun J, 2014 Crowdsourcing awareness: Exploration of the ovarian cancer knowledge gap through Amazon Mechanical Turk. *PloS One* 9, e85508 10.1371/journal.pone.0085508. [PubMed: 24465580]
- Courtemanche CJ, Palmer MK, Pesko MF, 2017 Influence of the flavored cigarette ban on adolescent tobacco use. *Am. J. Prev. Med* 52, e139–e146. 10.1016/j.amepre.2016.11.019. [PubMed: 28081999]
- Delnevo CD, Hrywna M, Foulds J, Steinberg MB, 2004 Cigar use before and after a cigarette excise tax increase in New Jersey. *Addict. Behav* 29, 1799–1807. 10.1016/j.addbeh.2004.04.024. [PubMed: 15530722]
- Denlinger RL, Smith TT, Murphy SE, Koopmeiners JS, Benowitz NL, Hatsukami DK, Pacek LR, Colino C, Cwalina SN, Donny EC, 2016 Nicotine and anatabine exposure from very low nicotine content cigarettes. *Tob. Regul. Sci* 2, 186–203. 10.18001/TRS.2.2.9. [PubMed: 29600258]
- Dermoddy SS, Tidey JW, Denlinger RL, Pacek LR, al'Absi M, Drobes DJ, Hatsukami DK, Vandrey R, Donny EC, 2016 The impact of smoking very low nicotine content cigarettes on alcohol use. *Alcohol. Clin. Exp. Res* 40, 606–615. 10.1111/acer.12980. [PubMed: 26916879]
- Donny EC, Denlinger RL, Tidey JW, Koopmeiners JS, Benowitz NL, Vandrey RG, al'Absi M, Carmella SG, Cinciripini PM, Dermoddy SS, Drobes DJ, Hecht SS, Jensen J, Lane T, Le CT, McClernon FJ, Montoya ID, Murphy SE, Robinson JD, Stitzer ML, Strasser AA, Tindle H, Hatsukami DK, 2015 Randomized trial of reduced-nicotine standards for cigarettes. *N. Engl. J. Med* 373, 1340–1349. 10.1056/NEJMs1502403. [PubMed: 26422724]
- Donny EC, Walker N, Hatsukami D, Bullen C, 2017 Reducing the nicotine content of combusted tobacco products sold in New Zealand. *Tob. Control* 26, e37–e42. 10.1136/tobaccocontrol-2016-053186. [PubMed: 27672126]
- Hatsukami DK, Kotlyar M, Hertsgaard LA, Zhang Y, Carmella SG, Jensen JA, Allen SS, Shields PG, Murphy SE, Stepanov I, Hecht SS, 2010 Reduced nicotine content cigarettes: Effects on toxicant exposure, dependence and cessation. *Addiction* 105, 343–355. 10.1111/j.1360-0443.2009.02780.x. [PubMed: 20078491]
- Hatsukami DK, Luo X, Dick L, Kangkum M, Allen SS, Murphy SE, Hecht SS, Shields PG, al'Absi M, 2017 Reduced nicotine content cigarettes and use of alternative nicotine products: Exploratory trial. *Addiction* 112, 156–167. 10.1111/add.13603. [PubMed: 27614097]
- Hatsukami DK, Vogel RI, Severson HH, Jensen JA, O'Connor RJ, 2016 Perceived health risks of snus and medicinal nicotine products. *Nicotine Tob. Res* 18, 794–800. 10.1093/ntr/ntv200. [PubMed: 26386473]
- Hawkins SS, Bach N, Baum CF, 2018 Impact of tobacco control policies on adolescent smokeless tobacco and cigar use: A difference-in-differences approach. *BMC Public Health* 18, 154 10.1186/s12889-018-5063-z. [PubMed: 29444658]
- Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO, 1991 The Fagerström Test for Nicotine Dependence: A revision of the Fagerström Tolerance Questionnaire. *Br. J. Addict* 86, 1119–1127. [PubMed: 1932883]
- Johnson MW, Johnson PS, Rass O, Pacek LR, 2017 Behavioral economic substitutability of e-cigarettes, tobacco cigarettes, and nicotine gum. *J. Psychopharmacol* 31, 851–860. 10.1177/0269881117711921. [PubMed: 28612651]
- Johnson PS, Herrmann ES, Johnson MW, 2015 Opportunity costs of reward delays and the discounting of hypothetical money and cigarettes. *J. Exp. Anal. Behav* 103, 87–107. 10.1002/jeab.110. [PubMed: 25388973]
- Mercincavage M, Souprontchouk V, Tang KZ, Dumont RL, Wileyto EP, Carmella SG, Hecht SS, Strasser AA, 2016 A randomized controlled trial of progressively reduced nicotine content cigarettes on smoking behaviors, biomarkers of exposure, and subjective ratings. *Cancer Epidemiol. Biomarkers Prev* 25, 1125–1133. 10.1158/1055-9965.EPI-15-1088. [PubMed: 27197288]
- Mortensen K, Hughes TL, 2018 Comparing Amazon's Mechanical Turk platform to conventional data collection methods in the health and medical research literature. *J. Gen. Intern. Med* 33, 533–538. 10.1007/s11606-017-4246-0. [PubMed: 29302882]

- Pacek LR, Rass O, Johnson MW, 2017 Knowledge about nicotine among HIV-positive smokers: Implications for tobacco regulatory science policy. *Addict. Behav* 65, 81–86. 10.1016/j.addbeh.2016.10.008. [PubMed: 27792909]
- Pacek Vandrey, R., Dermody SS, Denlinger-Apte RL, Lemieux A, Tidey JW, McClernon FJ, Bangdiwala AS, Drobes DJ, al'Absi M, Strasser AA, Koopmeiners JS, Hatsukami DK, Donny EC, 2016 Evaluation of a reduced nicotine product standard: Moderating effects of and impact on cannabis use. *Drug Alcohol Depend.* 167, 228–232. 10.1016/j.drugalcdep.2016.08.620. [PubMed: 27590743]
- Pacek Wiley, J.L., McClernon FJ, 2018 A conceptual framework for understanding multiple tobacco product use and the impact of regulatory action. *Nicotine Tob. Res* [Epub ahead of print].
- Qualtrics Support, 2018 Survey Protection. <https://www.qualtrics.com/support/surveyplatform/survey-module/survey-options/survey-protection>.
- Rass O, Pacek LR, Johnson PS, Johnson MW, 2015 Characterizing use patterns and perceptions of relative harm in dual users of electronic and tobacco cigarettes. *Exp. Clin. Psychopharmacol* 23, 494–503. 10.1037/pha0000050. [PubMed: 26389638]
- Richardson A, Williams V, Rath J, Villanti AC, Vallone D, 2014 The next generation of users: Prevalence and longitudinal patterns of tobacco use among US young adults. *Am. J. Public Health* 104, 1429–1436. 10.2105/AJPH.2013.301802. [PubMed: 24922152]
- Smith TT, Cassidy RN, Tidey JW, Luo X, Le CT, Hatsukami DK, Donny EC, 2017 Impact of smoking reduced nicotine content cigarettes on sensitivity to cigarette price: Further results from a multi-site clinical trial. *Addiction* 112, 349–359. 10.1111/add.13636. [PubMed: 27741367]
- Soneji S, Sargent J, Tanski S, 2016 Multiple tobacco product use among US adolescents and young adults. *Tob. Control* 25, 174–180. 10.1136/tobaccocontrol-2014-051638. [PubMed: 25361744]
- StataCorp, 2017 Stata Statistical Software: Release 15. StataCorp LLC, College Station, TX.
- Tidey JW, Pacek LR, Koopmeiners JS, Vandrey R, Nardone N, Drobes DJ, Benowitz NL, Dermody SS, Lemieux A, Denlinger RL, Cassidy R, al'Absi M, Hatsukami DK, Donny EC, 2017 Effects of 6-week use of reduced-nicotine content cigarettes in smokers with and without elevated depressive symptoms. *Nicotine Tob. Res* 19, 59–67. 10.1093/ntr/ntw199. [PubMed: 27613885]
- U.S. Congress, 2009 Family Smoking Prevention and Tobacco Control Federal Reform Act.
- U.S. Department of Health and Human Services (USDHHS), 2014 The Health Consequences of Smoking - 50 Years of Progress. A Report of the Surgeon General. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, GA.
- U.S. Food and Drug Administration (FDA), 2018 Advanced Notice of Proposed Rulemaking: Regulation of Flavors in Tobacco Products.
- U.S. Food and Drug Administration (FDA), 2013 Preliminary Scientific Evaluation of the Possible Public Health Effects of Menthol versus Nonmenthol Cigarettes. Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD.
- Villanti AC, Collins LK, Niaura RS, Gagosian SY, Abrams DB, 2017 Menthol cigarettes and the public health standard: A systematic review. *BMC Public Health* 17, 983 10.1186/s12889-017-4987-z. [PubMed: 29284458]

Highlights

- Hypothetical nicotine reduction led to intentions to quit/reduce cigarette use
- Hypothetical nicotine reduction led to intentions to increase e-cigarette use
- Menthol restrictions led to trends for increasing e-cigarette use

Figure 1.

Anticipated e-cigarette and combusted cigarette use in response to hypothetical regulation of nicotine content (A) and menthol (B) in combusted cigarettes; Data collected via Amazon Mechanical Turk, June 2017.

Note: Asterisks indicate statistically significant differences between product use categories; # indicates a trend for statistical significance ($p=0.080$)

Table 1.

Characteristics of dual combusted cigarette and e-cigarette users age 18–29, Amazon Mechanical Turk, June 2017 (n=240)

Characteristic	Total sample (n=240)	Menthol smokers (n=126)
	n (%)	n (%)
Male sex	118 (49.2)	52 (41.6)
Age-mean (SD)	24.3 (2.8)	24.1 (2.9)
Race		
White	174 (72.5)	82 (65.1)
Black	34 (14.2)	23 (18.2)
Other	32 (13.3)	21 (16.7)
Non-Hispanic ethnicity	216 (90.0)	112 (88.9)
Education		
High school/GED	30 (12.5)	21 (16.7)
>High school/GED	210 (87.5)	105 (83.3)
Income		
<\$25,000	48 (20.0)	23 (18.3)
\$25,000–\$34,999	48 (20.0)	26 (20.6)
\$35,000–\$49,999	44 (18.3)	22 (17.5)
\$50,000–\$74,999	45 (18.8)	22 (17.5)
\$75,000–\$99,999	33 (13.8)	21 (16.7)
\$100,000	21 (8.9)	12 (9.5)
Prefer not to answer	1 (0.4)	0
Marital status		
Not married	183 (76.3)	96 (76.2)
Married	57 (23.7)	30 (23.8)
Perceived risk of CC ^a -mean (SD)	7.1 (2.3)	7.3 (2.1)
Perceived risk of EC ^b -mean (SD)	4.6 (2.4)	4.7 (2.4)

^aCC = combusted cigarette

^bEC = e-cigarette

Table 2.

E-cigarette and combustible cigarette use characteristics of dual users age 18–29, Amazon Mechanical Turk, June 2017 (n=240)

Characteristic	EC	CC
	Mean (SD)	Mean (SD)
Years used	1.7 (1.9)	5.8 (3.8)
Bouts per day/CPD ^c	16.9 (29.5)	5.9 (5.4)
Days used per week	4.8 (2.1)	5.3 (2.1)
Daily use-n (%)	92 (38.3)	112 (46.7)
eFTND/FTND ^d	2.7 (2.3)	3.0 (2.4)
Plans to quit in next month-n (%)	67 (27.9)	155 (64.6)
Menthol-n (%)	--	126 (52.5)

^cCPD = cigarettes per day

^deFTND = e-cigarette Fagerström Test for Nicotine Dependence; FTND = Fagerström Test for Nicotine Dependence